BRAF immunohistochemistry predicts sentinel lymph node involvement in intermediate thickness melanomas.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
13
09
2018
accepted:
12
04
2019
entrez:
1
5
2019
pubmed:
1
5
2019
medline:
9
1
2020
Statut:
epublish
Résumé
Sentinel node biopsy (SNB) is an important step in melanoma staging and prognostication. It is commonly performed for patients with intermediate thickness melanomas, based on clinicopathological features. However, only 20-25% of patients eventually demonstrate nodal involvement. The aim of this study was to evaluate whether tissue biomarkers with links to melanoma biology, together with clinicopathological parameters, could aid in the prediction of sentinel node involvement and improve selection of patients for SNB. In addition, we examined the role of these clinical or biological markers in disease outcome. We collected a case-control cohort of 140 intermediate thickness (Breslow 0,9-4,0mm) melanoma patients with or without SNB involvement matched for age, gender, Breslow thickness and location. From this cohort, we tested the predictive value of common clinicopathological parameters (ulceration, mitotic count and tumor regression) and FMNL-2, ezrin and BRAF V600E immunoreactivity, for sentinel node involvement and survival. We further analyzed the correlations in the superficial spreading melanoma subtype. Based on our case control analysis, of the markers, BRAF V600E status (p = 0.010) and mitotic count (p = 0.036) correlated with SNB involvement. SNB status was a strong independent prognosticator for recurrence free survival (RFS p<0.001), melanoma specific survival (MSS p = 0.000) and overall survival (OS p = 0.029). In the superficially spreading melanoma subgroup, BRAF V600E positivity indicated poorer RFS (p = 0.039) and OS (p = 0.012). By combining the Breslow thickness, mitotic count and BRAF immunohistochemistry, we identified a group of superficially spreading melanomas with an excellent survival probability independent of SNB status. These results demonstrate that BRAF immunohistochemistry could serve as a useful addition to a marker panel for selecting intermediate thickness melanoma patients for SNB.
Sections du résumé
BACKGROUND
Sentinel node biopsy (SNB) is an important step in melanoma staging and prognostication. It is commonly performed for patients with intermediate thickness melanomas, based on clinicopathological features. However, only 20-25% of patients eventually demonstrate nodal involvement. The aim of this study was to evaluate whether tissue biomarkers with links to melanoma biology, together with clinicopathological parameters, could aid in the prediction of sentinel node involvement and improve selection of patients for SNB. In addition, we examined the role of these clinical or biological markers in disease outcome.
METHODS
We collected a case-control cohort of 140 intermediate thickness (Breslow 0,9-4,0mm) melanoma patients with or without SNB involvement matched for age, gender, Breslow thickness and location. From this cohort, we tested the predictive value of common clinicopathological parameters (ulceration, mitotic count and tumor regression) and FMNL-2, ezrin and BRAF V600E immunoreactivity, for sentinel node involvement and survival. We further analyzed the correlations in the superficial spreading melanoma subtype.
RESULTS
Based on our case control analysis, of the markers, BRAF V600E status (p = 0.010) and mitotic count (p = 0.036) correlated with SNB involvement. SNB status was a strong independent prognosticator for recurrence free survival (RFS p<0.001), melanoma specific survival (MSS p = 0.000) and overall survival (OS p = 0.029). In the superficially spreading melanoma subgroup, BRAF V600E positivity indicated poorer RFS (p = 0.039) and OS (p = 0.012). By combining the Breslow thickness, mitotic count and BRAF immunohistochemistry, we identified a group of superficially spreading melanomas with an excellent survival probability independent of SNB status.
CONCLUSIONS
These results demonstrate that BRAF immunohistochemistry could serve as a useful addition to a marker panel for selecting intermediate thickness melanoma patients for SNB.
Identifiants
pubmed: 31039200
doi: 10.1371/journal.pone.0216043
pii: PONE-D-18-26870
pmc: PMC6490950
doi:
Substances chimiques
FMNL2 protein, human
0
Formins
0
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0216043Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Am J Pathol. 1996 Feb;148(2):367-73
pubmed: 8579099
Cancer Cell. 2004 Feb;5(2):113-4
pubmed: 14998486
Hum Pathol. 2015 Feb;46(2):169-75
pubmed: 25442222
Cell Rep. 2016 May 31;15(9):2012-24
pubmed: 27210749
J Clin Oncol. 2011 Apr 1;29(10):1239-46
pubmed: 21343559
Dev Cell. 2006 Jun;10(6):693-706
pubmed: 16740473
J Dermatol. 2013 Dec;40(12):973-9
pubmed: 24303922
Mod Pathol. 2018 Jan;31(1):24-38
pubmed: 29148538
Cell Cycle. 2005 Oct;4(10):1382-4
pubmed: 16096377
Mod Pathol. 2005 Apr;18(4):503-10
pubmed: 15475929
Int J Oncol. 2014 Aug;45(2):516-24
pubmed: 24899250
Pigment Cell Melanoma Res. 2017 Jan;30(1):13-27
pubmed: 27900851
Curr Biol. 2012 Jun 5;22(11):1005-12
pubmed: 22608513
J Am Acad Dermatol. 2014 May;70(5):858-62.e1-2
pubmed: 24388723
Ann Surg Oncol. 2006 Mar;13(3):302-9
pubmed: 16485151
Br J Dermatol. 2015 Jul;173(1):76-82
pubmed: 25752325
Invest Ophthalmol Vis Sci. 2001 Oct;42(11):2442-9
pubmed: 11581181
CA Cancer J Clin. 2017 Nov;67(6):472-492
pubmed: 29028110
BMC Cell Biol. 2010 Jul 15;11:55
pubmed: 20633255
J Pathol Clin Res. 2016 Jan 21;2(1):41-52
pubmed: 27499915
MMWR Morb Mortal Wkly Rep. 2015 Jun 5;64(21):591-6
pubmed: 26042651
N Engl J Med. 2014 Feb 13;370(7):599-609
pubmed: 24521106
Oncotarget. 2016 Jul 19;7(29):45671-45677
pubmed: 27344178
Clin Cancer Res. 2012 Jun 15;18(12):3242-9
pubmed: 22535154
Oncogene. 2012 Jan 19;31(3):306-21
pubmed: 21725352
J Clin Oncol. 2009 Dec 20;27(36):6199-206
pubmed: 19917835
Br J Cancer. 2017 Sep 26;117(7):1026-1035
pubmed: 28787433